Market open
Allakos/$ALLK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Allakos
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.
Ticker
$ALLK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
131
ISIN
US01671P1003
Website
Allakos Metrics
BasicAdvanced
$30M
-
-$0.79
0.14
-
Price and volume
Market cap
$30M
Beta
0.14
52-week high
$1.51
52-week low
$0.22
Average daily volume
1.6M
Financial strength
Current ratio
14.234
Quick ratio
13.535
Management effectiveness
Return on assets (TTM)
-52.64%
Return on equity (TTM)
-88.87%
Valuation
Price to book
0.54
Price to tangible book (TTM)
0.54
Growth
Earnings per share change (TTM)
-67.72%
3-year earnings per share growth (CAGR)
-52.88%
What the Analysts think about Allakos
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Allakos stock.
Allakos Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Allakos Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Allakos News
AllArticlesVideos
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders
Business Wire·1 month ago
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
GlobeNewsWire·1 month ago
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Allakos stock?
Allakos (ALLK) has a market cap of $30M as of May 16, 2025.
What is the P/E ratio for Allakos stock?
The price to earnings (P/E) ratio for Allakos (ALLK) stock is 0 as of May 16, 2025.
Does Allakos stock pay dividends?
No, Allakos (ALLK) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Allakos dividend payment date?
Allakos (ALLK) stock does not pay dividends to its shareholders.
What is the beta indicator for Allakos?
Allakos (ALLK) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.